Kura Oncology, a San Diego biopharmaceutical company, was recently featured in a Globe Newswire article, announcing its first-in-human dose escalation of KO-539 being evaluated in the Komet-001 trial (NCT04067336). The…
If you're like me, you've probably been listening to a lot of podcasts over this past year while stuck at home or in quarantine. While my typical podcast selection centers…
According to a story from Charcot-Marie-Tooth News, the National Organization for Rare Disorders (NORD) is beginning a new initiative that will be the focus of a public virtual meeting that…
by Lauren Taylor from In The Cloud Copy A variance in the amount or makeup of the bacteria in a person’s gut, called dysbiosis, could have strong implications for the…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
